Want to join the conversation?
Drugmaker $PFE said the Phase 3 SPIRE-AI trial of the Proprotein Convertase Subtilisin Kexin type 9 inhibitor bococizumab administered with a pre-filled pen met its co-primary endpoints, the percent change from baseline in low-density lipoprotein cholesterol reduction at 12 weeks versus placebo and number of patients operating the AI successfully.
Still in yesterday’s $PZZA shock. I thought everyone had more pizza this football season!!
$TSLA stock downgraded to sell from hold by brokerage firm CFRA Research. However, the firm lifted the price target by $35 to $240.
$LB shares have plummeted after a disappointing quarter.